2024
Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions: A Systematic Review and Meta-Analyses.
Siddiqi T, Cherney D, Siddiqui H, Jafar T, Januzzi J, Khan M, Levin A, Marx N, Rangaswami J, Testani J, Usman M, Wanner C, Zannad F, Butler J. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions: A Systematic Review and Meta-Analyses. Journal Of The American Society Of Nephrology 2024 PMID: 39230974, DOI: 10.1681/asn.0000000000000491.Peer-Reviewed Original ResearchSodium-glucose cotransporter-2 inhibitorsType 2 diabetes mellitusChronic kidney diseaseEffects of sodium-glucose cotransporter-2 inhibitorsComposite kidney endpointCotransporter-2 inhibitorsKidney outcomesHeart failureKidney diseaseKidney endpointsHazard ratioDoubling of serum creatinineCombination of heart failureSustained doubling of serum creatininePlacebo-controlled trialReduced ejection fractionBaseline heart failureConfidence intervalsRandom-effects modelAlbuminuria progressionEjection fractionSerum creatinineReview ManagerMellitusPatientsSodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia REALIZE-K Design and Baseline Characteristics
Kosiborod M, Cherney D, Connelly K, Desai A, Guimarães P, Kuthi L, Lala A, Madrini V, Merkely B, Villota J, Squire I, Testani J, Vaclavik J, Verma S, Wranicz J, Dahl M, Eudicone J, Friberg L, Petrie M. Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia REALIZE-K Design and Baseline Characteristics. JACC Heart Failure 2024, 12: 1707-1716. PMID: 38878009, DOI: 10.1016/j.jchf.2024.05.003.Peer-Reviewed Original ResearchMineralocorticoid receptor antagonistsSodium zirconium cyclosilicateZirconium cyclosilicateBaseline characteristicsOpen-label run-inN-terminal pro B-type natriuretic peptideMineralocorticoid receptor antagonist useRun-inPro B-type natriuretic peptideB-type natriuretic peptidePlacebo-controlled trialRisk of hyperkalemiaReduced ejection fractionPrimary composite endpointDouble-blindEjection fractionReceptor antagonistLowered potassiumOptimal therapyNatriuretic peptideIncident hyperkalemiaProportion of participantsTherapy useHFrEFComposite endpoint
2021
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial.
Szarek M, Bhatt DL, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Banks P, Tesfaye E, Ezekowitz JA, Verma S, Pitt B. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. Annals Of Internal Medicine 2021, 174: 1065-1072. PMID: 34152828, DOI: 10.7326/m21-0651.Peer-Reviewed Original ResearchConceptsHeart failurePlacebo groupType 2 diabetesSotagliflozin groupRate of daysSodium-glucose cotransporter 2 inhibitorsEffect of sotagliflozinPrespecified efficacy outcomeWorsening Heart FailureDuration of admissionPlacebo-controlled trialCotransporter 2 inhibitorsPatient-centered outcomesSodium-glucose cotransporter 1Poisson regression modelsCardiovascular deathEfficacy outcomesTotal hospitalizationsUrgent visitsEjection fractionPatients' qualityDisease burdenSotagliflozinHospitalizationPatients